STRIDE‐PD (STalevo Reduction In Dyskinesia Evaluation) is still the only controlled trial to investigate this possibility and has failed to demonstrate that initiating LD therapy with a COMT inhibitor (entacapone) can delay the time of onset or reduce the frequency of dyskinesia compared with LD‐only therapy.26 This evidence concerns the gene COMT and drug-induced dyskinesia.